Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
For Combination Therapy
RUBY Clinical Data Slide Deck
A summary presentation of the RUBY Clinical Trial data
SPOTLIGHT: Webinar Series Highlights
Exploring the current and evolving landscape of Endometrial Cancer – Dr. Rebecca Kristeleit
Dr. Kristeleit talks to the unmet need in primary advanced/ recurrent endometrial cancer, and the importance of biomarker testing to identify the appropriate patient
Impacting clinical practice in primary advanced/recurrent dMMR/MSI-H endometrial cancer: An expert panel discussion
Dr. Nicum discusses with Dr. Mirza and Dr. Kristeleit about how to implement the RUBY trial data in clinical practise, sharing their experience of patient identification, biomarker testing and management of patients on Jemperli
Dosing and Administration
If you would like to request printed booklets, get in touch with your local representative
Do you have questions about how JEMPERLI can support your patients?
Indications
JEMPERLI is indicated in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient dMMR/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.
JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.
Footnotes
Anti-PD-1, anti-programmed death-1, CP, carboplatin/paclitaxel; dMMR, mismatch repair deficient; EC, endometrial cancer; MSI-H, microsatellite instability high
References
- Mirza MR, et al. Dostarlimab for primary advanced recurrent endometrial cancer. N Eng J Med. 2023;388(23):2145-2158
- Jemperli (dostarlimab) Summary of Product Characteristics, Great Britain. Accessed December 2023.
Adverse events should be reported.
Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/ (UK) or search for MHRA Yellow Card in the Google Play or Apple App store.
Adverse events should also be reported to GSK Limited on 0800 221 441 or uksafety@gsk.com
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
December 2023 ӏ PM-GB-DST-WCNT-230025 (V1.0)
